Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dapsone Coronavirus SARS-CoV-2 Trial (DAP-CORONA) COVID-19 (DAP-CORONA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04935476
Recruitment Status : Recruiting
First Posted : June 23, 2021
Last Update Posted : November 24, 2021
Sponsor:
Collaborator:
Pulmonem Inc.
Information provided by (Responsible Party):
Jean Bourbeau, McGill University Health Centre/Research Institute of the McGill University Health Centre

Brief Summary:

This is a multi-center, randomized, triple-blind, placebo-controlled (RCT) study to evaluate the efficacy and safety of Dapsone in older adults, and/or in adult patients (≥40yrs of age) with at least one high-risk comorbidity, among those with confirmed SARS-CoV-2 infection.

3000 infected patients diagnosed with COVID-19, non-hospitalized at the time of enrollment, meeting all inclusion and no exclusion criteria will be randomized (1:1 allocation ratio) to receive either Dapsone or placebo tablets for 21 days, and will be followed up for 7 days after treatment termination for outcome assessment and up to 30 days for safety monitoring.


Condition or disease Intervention/treatment Phase
COVID-19 Drug: Dapsone 85 mg PO BID Drug: Placebo 85 mg PO BID Phase 3

Detailed Description:

The primary objective of this study is to determine whether early treatment with Dapsone reduces pulmonary complications related to COVID-19 and consequent hospitalization in high-risk group of elderly adults and adults (≥40yrs of age) with comorbidity.

The secondary objectives are to determine the effect of Dapsone on reducing severe complications related to COVID-19 (ICU, intubation and death) and the safety of treatment with Dapsone in this high-risk COVID-19 patient population.

3000 patients will be enrolled to receive either Dapsone or placebo (1:1 allocation ratio) for 21 days. Follow-up assessments will occur remotely through participant e-daily diary and virtual visits (electronically via internet and/or telephone) at Day 1(start of study drug), 7, 14, 21, 28 and 51 following randomization in order to document the occurrence of any trial endpoints.

Safety and efficacy will be based on data from randomized patients. An independent data and safety monitoring committee (DSMC) will periodically review study results and will make recommendations to the study Steering Committee for continuing the trial as planned (or with modification) or for stopping early for safety concerns.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 3000 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

This is a randomized, triple-blind, placebo-controlled, multi-center study.

Following e-signature of the informed consent form, approximately 3000 participants meeting all inclusion criteria and no exclusion criteria will be randomized to receive either Dapsone or placebo (1:1 allocation ratio) for 21 days. Screening blood-work and confirmatory tests are made available to participants at their residence by the study. Study interventions (drugs or placebo) will be delivered directly to participants by courier .

Participants are remotely followed-up through e-daily diary during 21 days of treatment along with virtual visits (phone) at 1, 7, 14, 21, 28 and 51 days following randomization for evaluation of the occurrence of any trial endpoints or other adverse events. During study enrollment patients are linked to the study through their participant account on the study virtual care platform.

Masking: Triple (Participant, Investigator, Outcomes Assessor)
Masking Description: Triple (Participant, study staff and data analyst)
Primary Purpose: Treatment
Official Title: A Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Dapsone for the Treatment of COVID-19 Positive Patients.
Actual Study Start Date : November 22, 2021
Estimated Primary Completion Date : March 31, 2022
Estimated Study Completion Date : July 31, 2022

Resource links provided by the National Library of Medicine

Drug Information available for: Dapsone

Arm Intervention/treatment
Active Comparator: Treatment

Participants will receive standard of care and Dapsone per os (PO) twice daily for 21 days. If a dose is missed, it should not be replaced.

Dosage form: Dapsone oral tablet

Drug: Dapsone 85 mg PO BID
Participants will receive standard of care and study medication Dapsone 85 mg per os (PO) twice daily for 21 days. If a dose is missed, it will not be replaced.
Other Name: diaminodiphenyl sulfone (DDS)

Placebo Comparator: Control

Participants will receive standard of care and placebo per os (PO) twice daily for 21 days. If a dose is missed, it should not be replaced.

Dosage form: Placebo oral tablet

Drug: Placebo 85 mg PO BID
Placebo oral tablet, twice daily for 21 days.
Other Name: Placebo




Primary Outcome Measures :
  1. Composite outcome: All cause pre-hospitalization death or all-cause hospitalization [ Time Frame: 30 days post randomization ]
    Number of participants requiring hospitalization or die prior to hospitalization in the first 30 days after randomization.


Secondary Outcome Measures :
  1. Severe complications (composite outcome: All cause ICU admission, invasive ventilation or pre- or post-hospitalization death) [ Time Frame: 30 days post randomization ]
    Number of participants developing severe complications and need ICU admission, invasive ventilation or die in the first 30 days.

  2. All-cause ICU admission [ Time Frame: 30 days post randomization ]
    Number of participants requiring ICU admission in the first 30 days after randomization.

  3. Intubation with mechanical ventilation [ Time Frame: 30 days post randomization ]
    Number of participants requiring intubation with mechanical ventilation in the first 30 days after randomization.

  4. All-cause death [ Time Frame: 30 days post randomization ]
    Number of participants who die in the first 30 days after randomization.

  5. Hospitalization with all-cause requirement of supplemental oxygen [ Time Frame: 30 days post randomization ]
    Number of participants requiring hospitalization with supplemental oxygen in the first 30 days after randomization.

  6. Length of hospital stay among participants [ Time Frame: 30 days post randomization ]
    Duration of hospitalization among study participants requiring hospitalization in the first 30 days after randomization.

  7. Drug safety (Adverse Event (AE) and Serious Adverse Event (SAE)) for short term therapy in COVID-19 patients [ Time Frame: 30 days post randomization ]
    Number of participants developing AE and SAE in the first 30 days post randomization.

  8. Patient reported outcome (e.g. patient reported COVID-19 related symptoms) [ Time Frame: 30 days post randomization ]
    Trajectory of participant reported COVID-19 related symptoms among study participants in the first 30 days after randomization.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female aged ≥ 40 years;
  2. Symptomatic adults with confirmed COVID-19 (SARS-COV-2 PCR positive) for at least 24 hrs. and no more than 7 days: by report or observation, including one or more of the following: temperature ≥ 38°C (≥100.4°F), chills or shivering, cough, difficulty breathing, fatigue, headache, muscle or body ache, anosmia (loss of smell) and/or dysgeusia (loss of taste), GI symptoms (nausea and/or vomiting);

(3a) Aged ≥70 years or above, presence of concomitant comorbidity not required for inclusion

or

(3b) Aged ≥40 to <70 years, and presence of at least one of the following concomitant comorbidities by report, history, or observation:

  • Cardiovascular diseases (e.g., hypertension, coronary artery diseases, congestive heart failure, symptomatic arrhythmia, transient brain ischemia, stroke)
  • Chronic respiratory diseases (e.g., Chronic Obstructive Pulmonary Disease (COPD), asthma, pulmonary fibrosis)
  • Obesity (BMI >30 kg/m^2)
  • Type 2 Diabetes
  • Cancer (participant reported: stable >6 months as per treating doctor/oncologist)
  • Autoimmune diseases (T1D, RA, PA, MS, IBD, AD, SS, HT, SLE)

    (4) Participant is considered suitable for continued management in the out-patient setting.

    (5) Non-pregnant non-breastfeeding women of reproductive age group not planning pregnancy and/or adopting advised contraception during the study and for 3 months after the last dose of study medication.

Exclusion Criteria:

  1. Unable to provide consent; diagnosis of dementia or other significant neurocognitive disorder;
  2. Current hospitalization;
  3. Patient requiring long term oxygen treatment of > 5 L O2/min because of a chronic lung condition at time of recruitment;
  4. Known intolerance/allergy to sulfone;
  5. Pregnant or breastfeeding women or is considering becoming pregnant during the study and for 3 months after the last dose of study medication;
  6. Concurrent malignancy on systemic chemotherapy or immunotherapy;
  7. Significantly impaired renal function within the past year reported by history and estimated glomerular filtration rate (eGFR) < 60 mL/min at screening
  8. Severely underweight (≤ 40 kg)
  9. G6PD deficiency (previous jaundice, jaundice with foods such as beans, or medication such as sulfa drugs, NSAIDs, quinolones, hydroxychloroquine or vitamin C), significant blood dyscrasia or anemia (Hb <12.0 g/dL in women and <13.0 g/dL in men; platelet count <50 x 10^9/L or < lower limit of normal at screening)
  10. Impairment liver function [> 2 times the upper limit of normal (ULN) at screening at screening for AST, ALT, ALP, GGT, albumin or bilirubin), liver cirrhosis or hepatitis
  11. Current use of folic acid antagonists (such as pyrimethamine), nitrofurantoin or primaquine
  12. Currently taking oral dapsone for dermatological or other indications
  13. Currently taking hydroxychloroquine or if have taken it within the last 6 months
  14. Currently on any of the following medications: Aminolevulinic acid; Cladribine; Clozapine; Deferiprone; Prilocaine; Saquinavir; Sodium nitrite, Rifampin or St. John's wort
  15. Received any of the following vaccines in the last 1 year : Cholera vaccine live; Typhoid vaccine, live; BCG (Bacillus Calmette and Guérin)
  16. Currently taking any the following anticonvulsants : carbamazepine, phenytoin, levetiracetam and gabapentin
  17. Currently participating in other interventional trials
  18. Inability to provide contact details of caregiver/ next of kin to be contacted for study follow-up as participant's surrogate
  19. Currently taking trimethoprim

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04935476


Contacts
Layout table for location contacts
Contact: Sharmistha Biswas 1-866-327-2728 sharmistha.biswas@mail.mcgill.ca
Contact: María F Sedeño 1-866-327-2728 maria.sedeno@mail.mcgill.ca

Locations
Layout table for location information
United States, Arizona
Arizona Pulmonary and Medical Specialists Not yet recruiting
Phoenix, Arizona, United States, 85012
Contact: Melina Calles       Melina.Calles@DignityHealth.org   
United States, North Carolina
Peters Medical Research, LLC Recruiting
High Point, North Carolina, United States, 27262
Contact: Anita McPherson       anitam@petersmedicalresearch.com   
United States, Pennsylvania
Temple University Hospital Not yet recruiting
Philadelphia, Pennsylvania, United States, 19140
Contact: Laurie Jameson       laurie.jameson@tuhs.temple.edu   
University of Pittsburgh UPMC Not yet recruiting
Pittsburgh, Pennsylvania, United States, 15213
Contact: Joshua Hulbert       hulbertjc@upmc.edu   
United States, Washington
Principle Research Solutions Recruiting
Spokane, Washington, United States, 99204
Contact: Christi Witte       christi@principleresearchsolutions.com   
Canada, Ontario
Inspiration Research Limited Not yet recruiting
Toronto, Ontario, Canada, M5T 3A9
Contact: Jane Duke       jduke@inspirationresearch.ca   
Canada, Quebec
McGill University Health Centre Not yet recruiting
Montreal, Quebec, Canada, H4A 3J1
Contact: Palmina Mancino       palmina.mancino@mcgill.ca   
Sponsors and Collaborators
McGill University Health Centre/Research Institute of the McGill University Health Centre
Pulmonem Inc.
Investigators
Layout table for investigator information
Principal Investigator: Jean Bourbeau, MD,MSc,FRCPC RI-MUHC
Layout table for additonal information
Responsible Party: Jean Bourbeau, Principal Investigator, McGill University Health Centre/Research Institute of the McGill University Health Centre
ClinicalTrials.gov Identifier: NCT04935476    
Other Study ID Numbers: PDC01
First Posted: June 23, 2021    Key Record Dates
Last Update Posted: November 24, 2021
Last Verified: November 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Jean Bourbeau, McGill University Health Centre/Research Institute of the McGill University Health Centre:
Dapsone
COVID-19
treatment for COVID-19
non-hospitalized patients
prophylaxis
SARS-COV-2
Clinical trials
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
Dapsone
Anti-Infective Agents
Antimalarials
Antiprotozoal Agents
Antiparasitic Agents
Folic Acid Antagonists
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Leprostatic Agents
Anti-Bacterial Agents